to verify the role in these patients of a combination therapy of amikacin ( 300 mg/m2 i.v . every 12 hours ) plus ceftazidime ( 2 g/m2 i.v . every 8 hours ) administered as initial empiric treatment , followed in non-responsive cases by a second-line therapy with clindamycin ( 300 mg/m2 i.v . every 8 hours ) , we conducted a prospective study in 45 febrile episodes ( temperature greater than or equal to 38.5 degrees c ) in neutropenic patients ( neutrophils less than or equal to 500/ml ) .
C0007559
ceftazidime
C0015967
febrile